In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The company is confident of addressing all the observations within the stipulated time
Subscribe To Our Newsletter & Stay Updated
